Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

NCT02191878 is registered in ClinicalTrials.gov with Arbutus Biopharma Corporation as lead sponsor.

NCT NCT02191878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02191878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Arbutus Biopharma Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2014
Completion date
July 31, 2016
Enrollment
43 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, hepatoma, liver cancer, adult, liver cell carcinoma, adult